evidencegaps
Findings

What do systematic reviews say?

Refine by population, intervention, comparison or outcome
More filters
Evidence found and GRADE certainty

604 questions · 627 findings · 38 reviews · Skin · Headline outcomes only

Sort:Best matchNewestHighest certaintyDownload CSV
No studies found 161 · 25.7%GRADE not reported 29 · 4.6%Very low 80 · 12.8%Low 139 · 22.2%Moderate 174 · 27.8%High 44 · 7%

Intervention not reported

Placebo · patients with moderate to severe eczema

The review found no eligible studies for this question.

1 finding from 1 review

Intervention not reported

Placebo · patients with moderate to severe eczema

The review found no eligible studies for this question.

1 finding from 1 review

Intervention not reported

Placebo · patients with moderate to severe eczema

The review found no eligible studies for this question.

1 finding from 1 review

Intervention not reported

Placebo · patients with moderate to severe eczema

The review found no eligible studies for this question.

1 finding from 1 review

Intervention not reported

Placebo · patients with moderate to severe eczema

The review found no eligible studies for this question.

1 finding from 1 review

Intervention not reported

Placebo · patients with moderate to severe eczema

The review found no eligible studies for this question.

1 finding from 1 review

Summary of findings table ‐ Oral classical immunosuppressants (prednisolone or cyclosporine) vs placebo

Short‐term hair regrowth ≥ 75% (between 12 and 26 weeks of · adults with alopecia areata

It is very uncertain whether summary of findings table ‐ Oral classical immunosuppressants… changes short‐term hair regrowth ≥ 75% (between 12 and 26 weeks of compared with placebo (very low certainty).

1 finding from 1 review

Summary of findings table ‐ Subcutaneous biologics (dupilumab) vs placebo

Short‐term hair regrowth ≥ 75% (between 12 and 26 weeks of · adults with alopecia areata

Summary of findings table ‐ Subcutaneous biologics (dupilumab) showed no clear difference in short‐term hair regrowth ≥ 75% compared with placebo (low certainty).

1 finding from 1 review

Summary of findings table ‐ Oral small molecule inhibitors (apremilast or baricitinib) vs placebo

Short‐term hair regrowth ≥ 75% (between 12 and 26 weeks of · adults with alopecia areata

Summary of findings table ‐ Oral small molecule inhibitors… leads to higher short‐term hair regrowth ≥ 75% (between 12 and 26 weeks of compared with placebo (high certainty).

1 finding from 1 review

Summary of findings table ‐ Oral small molecule inhibitors (apremilast or baricitinib) vs placebo

Incidence of serious adverse events · adults with alopecia areata

Summary of findings table ‐ Oral small molecule inhibitors… showed no clear difference in incidence of serious adverse events compared with placebo (low certainty).

1 finding from 1 review

Summary of findings table ‐ Oral small molecule inhibitors (apremilast or baricitinib) vs placebo

Long‐term hair regrowth ≥ 75% (greater than 26 weeks of · adults with alopecia areata

Summary of findings table ‐ Oral small molecule inhibitors… leads to higher long‐term hair regrowth ≥ 75% (greater than 26 weeks of compared with placebo (high certainty).

1 finding from 1 review

Summary of findings table ‐ Topical small molecule inhibitors (ruxolitinib) vs placebo

Short‐term hair regrowth ≥ 75% (between 12 and 26 weeks of · adults with alopecia areata

Summary of findings table ‐ Topical small molecule inhibitors… showed no clear difference in short‐term hair regrowth ≥ 75% (between 12 and 26 weeks of compared with placebo (low certainty).

1 finding from 1 review